Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Evaluation of cases of psychosis from opicapone safety data

Luis Guedes, MD, BIAL – Portela & Ca S.A., Coronado, Portugal, discusses the safety evaluation process for opicapone, a drug used in the treatment of Parkinson’s disease. Dr Guedes shares the results of an internal evaluation conducted for psychiatric symptoms associated with opicapone, highlighting that there was no confirmed causal association between taking the drug and psychotic disorders. He emphasizes the importance of this information for healthcare professionals in managing medications and considering other factors that could contribute to psychiatric symptoms. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Luis Guedes is an employee of BIAL.